Contineum Therapeutics
San Diego, California, United States · Biopharma, Biotechnology, Health Care
Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications. The company has a pipeline of internally-developed programs to address multiple NI&I disorders, primarily targeting biological pathways associated with specific clinical impairments. Contine
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (CTNM)
- Website
- www.contineum-tx.com
- Company page
Recent activity at Contineum Therapeutics
- : SEC 8-K (8.01): On September 14, 2026, Contineum Therapeutics, Inc. announced the results of the MOONLIGHT-1 Phase 2 clinical trial for JNJ-5120/PIPE-307 targeting major depressive disorder. The trial assessed the drug's efficacy, safety, and tolerability in adult participants. This drug is being developed by Johnson & Johnson under a global license and development agreement with Contineum, which is a significant collaboration for both companies in the mental health therapeutic area. The press release detailing the trial outcomes is attached as Exhibit 99.1.
- : SEC 8-K (7.01): On July 13, 2026, Contineum Therapeutics, Inc. updated its corporate presentation to include important business and strategic updates, which is significant for stakeholders. The updated presentation, available as Exhibit 99.1, is intended to keep investors informed about the company's direction and will be regularly updated on the company's website. This move indicates the company's commitment to transparent communication, although it plans to streamline such updates by not filing a Form 8-K for each change. The event date of this update is crucial as it reflects the company's current strategies and potential impacts on its market position.
- : SEC 8-K (8.01): On April 30, 2026, the Company announced topline data from its Phase 1b Trial of PIPE-791 in Chronic Pain, which primarily assessed the safety and tolerability of the treatment. The trial involved 43 patients with chronic osteoarthritic pain and chronic low back pain participating in a 4-week study designed to measure pain relief and adverse events. The trial found that PIPE-791 had a favorable AE profile, with mild to moderate treatment-emergent adverse events such as headache and fatigue reported, and improvements in pain intensity scores were observed compared to a placebo. This announcement highlights the company's progress in pain management research and potential implications for future treatments in the chronic pain sector, particularly as it reveals promising efficacy results that could influence market opportunities.
About Contineum Therapeutics: questions and answers
What does Contineum Therapeutics do?
Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications. The company has a pipeline of internally-developed programs to address multiple NI&I disorders, primarily targeting biological pathways associated with specific clinical impairments. Contine
Where is Contineum Therapeutics headquartered?
Contineum Therapeutics is headquartered in San Diego, California, United States.
What is the latest news on Contineum Therapeutics?
On Sep 14, 2026, SEC 8-K (8.01): On September 14, 2026, Contineum Therapeutics, Inc. announced the results of the MOONLIGHT-1 Phase 2 clinical trial for JNJ-5120/PIPE-307 targeting major depressive disorder. The trial assessed the drug's efficacy, safety, and tolerability in adult participants. This drug is being de
Is Contineum Therapeutics a public company?
Yes. Contineum Therapeutics is publicly traded under the ticker CTNM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy